This site is intended for US healthcare professionals only.

Some patients have inadequate or no response, or are ineligible for current treatment options3

~13,200 US patients with lower-risk MDS need treatment for symptomatic anemia16

ESA ineligible

1 in 10 have endogenous EPO levels high enough to make them ESA ineligible (EPO >500 mU/mL)13

~75%

Patients

When RS-negative patients
fail to respond or lose response to treatments, new options are needed17,18

~25%

Patients

A substantial proportion
of RS-positive patients continue to experience high transfusion burden despite available treatments17

Given the challenges that these patients face with current treatments, the need for novel options is crucial.3,6

EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; MDS, myelodysplastic syndromes; RS, ring sideroblasts.